Combined Nivolumab and Ipilimumab in Melanoma Metastatic to the

Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial - The Lancet Oncology

Nivolumab in Combination With Ipilimumab in BRAF V600 Wild-Type Unresectable or Metastatic Melanoma - The ASCO Post

Real World Outcomes of Ipilimumab and Nivolumab in Patients with Metastatic Melanoma - Document - Gale OneFile: Health and Medicine

Nivolumab-ipilimumab combination demonstrates antitumor activity in prostate cancer subset

Relatlimab/Nivolumab in Metastatic Melanoma: Data From the RELATIVITY-047 Trial

Full article: Efficacy and safety of the combined use of ipilimumab and nivolumab for melanoma patients with brain metastases: a systematic review and meta-analysis

Double Trouble: Immunotherapy Doublets in Melanoma—Approved and Novel Combinations to Optimize Treatment in Advanced Melanoma

VisualAbstract: Nivolumab plus ipilimumab may be less effective in females with melanoma compared to males

Nivolumab and ipilimumab: immunotherapy for treatment of malignant melanoma

Nivolumab plus ipilimumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial